Avyakta Law is pleased to announce its role as legal advisor to Micro Labs Limited, a fully integrated pharmaceutical company with headquarters in Bangalore, Karnataka, India, in its successful acquisition of Swiss Pharma Nigeria Limited (Swipha). This acquisition marks a significant milestone in Micro Labs’ strategic expansion in the Nigerian and broader African market.

Micro Labs, with a robust network of 14 formulation plants, including an injectable unit and bulk drug facility, operates international offices in key regions such as the United States, the United Kingdom, Germany, Australia, and Nigeria, as well as representative offices in emerging markets. In Nigeria, the company has operated through its subsidiary Micro Nova Pharmaceutical Ind. Limited for over a decade, establishing itself as a market leader in specialized therapeutic segments within the Nigerian pharmaceutical industry.

The Avyakta Law team, led by Managing Partner Mr. Shameek Chaudhuri, with Mr. Kshitij Goel, provided comprehensive legal support throughout the transaction, including advising on negotiation and drafting of transaction documents, addressing regulatory requirements across multiple jurisdictions, and assisting in the execution of the acquisition.

Swipha, established in 1976, is a leading pharmaceutical company in Nigeria, dedicated to delivering high-quality, affordable medicines to improve healthcare outcomes in Nigeria and across Africa. The company’s portfolio spans essential therapeutic areas, including central nervous system, anti-malaria, anti-infectives, cardiovascular health, and anti-diabetic medications. Notably, Swipha was the first in Nigeria, West, and Central Africa to attain WHO Pre-qualification for Zinc (Anti-Diarrhea) and Sulfadoxine-Pyrimethamine (Anti-Malaria) drugs, underscoring its commitment to quality and accessibility.

 This cross-border acquisition, involving jurisdictions including India, Nigeria, France, and the Netherlands, highlights the complexities of navigating various legal frameworks and regulatory environments.

 The purchase consideration for this transaction remains confidential.